Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05950152
Other study ID # MLI-RD85-P2-2023
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 2023
Est. completion date February 2024

Study information

Verified date July 2023
Source Beijing Tide Pharmaceutical Co., Ltd
Contact yangwen ou, medical doctor
Phone 0731-88618151
Email ouyangwen139@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the analgesic efficacy and safety of Meloxicam Injection in subjects undergoing abdominal surgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 108
Est. completion date February 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: Voluntarily provide written informed consent. Be scheduled to undergo elective abdominoplasty surgery without collateral procedures. Be American Society of Anesthesiology (ASA) physical class 1 or 2. Male or female between 18 and 70 years of age, inclusive. Have a body mass index 18~30 kg/m2. Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program. Exclusion Criteria: Have a history of abdominoplasty surgery within the preceding 12 months. Have active or recent (within 6 months) gastrointestinal ulceration or bleeding. Have a history of myocardial infarction or coronary artery bypass graft surgery within the preceding 12 months. Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other condition that would preclude participation in the study. Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants. Have another painful physical condition that may confound the assessments of post operative pain. Have a history of advanced malignant tumor. Have a history of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) within the past 5 years or a history of prescription/illicit drug abuse. Have positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse. Have evidence of a clinically significant 12 lead ECG abnormality. Have a clinically significant abnormal clinical laboratory test value. Have history of or positive test results for HIV, treponema pallidum,or hepatitis B or C. Have a known allergy to meloxicam or any excipient of N1539, D5W, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or to any peri- or postoperative medications used in this study. Have been receiving or have received chronic opioid therapy defined as greater than 15 morphine equivalents units per day for greater than 3 out of 7 days per week over a one-month period within 12 months of surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Meloxicam Injection 30mg
meloxicam injection 30mg every 24 hours for up to 2 dose
Meloxicam Injection 60mg
meloxicam injection 60mg every 24 hours for up to 2 dose
Nacl 0.9%
IV Placebo every 24 hours for up to 2 doses

Locations

Country Name City State
China the Third XiangYa Medical Hospital of Central South University Changsha Hunan

Sponsors (2)

Lead Sponsor Collaborator
Beijing Tide Pharmaceutical Co., Ltd The Third Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Summed Pain Intensity Difference Over the First 24 Hours (SPID24) Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better. 24 Hours
Secondary Summed Pain Intensity Difference (SPID) at Other Intervals Pain intensity was recorded using a Numeric Pain Rating Scale (Range 0-10) where 0 equates to no pain (better), and 10 equates to the worst pain imaginable (worse). Pain intensity scores were to be recorded at the following time points: 0.25, 0.5, 0.75, 1, and 2 hours post Dose 1. Thereafter pain assessments were to be recorded every 2 hours until 48 hours post Dose 1. Pain intensity differences from baseline at each time point were calculated and a time weighted summed pain intensity difference (SPID) was then calculated. Time weighted SPID calculations were computed by multiplying a weight factor to each score prior to summation. The weight factor at each time point was the time elapsed since the previous observation. A smaller SPID value (i.e. more negative) was better. 48 Hours
Secondary Time to First Dose of Rescue Analgesia Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request. Time to first rescue was calculated as the elapsed time from administration of Dose 1 to the administration of the first dose of rescue analgesia. 48 Hours
Secondary Number of Subjects Utilizing Rescue Analgesia Rescue analgesia (oral oxycodone 5 mg) was available to subjects with inadequately controlled pain upon request. 48 Hours
See also
  Status Clinical Trial Phase
Completed NCT02284243 - Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery Phase 2
Completed NCT02720692 - Evaluation of N1539 Following Major Surgery Phase 3
Completed NCT03456141 - Multimodal Analgesic Protocol to Moderate Acute Pain
Terminated NCT02169336 - Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Phase 2
Completed NCT02675907 - Evaluation of N1539 Following Bunionectomy Surgery Phase 3
Completed NCT02678286 - Evaluation of N1539 Following Abdominoplasty Surgery Phase 3
Unknown status NCT01041313 - Memantine for Post-Operative Pain Control Phase 4
Completed NCT02540265 - Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery Phase 2
Completed NCT03154658 - Serratus Anterior Plane Block in Patients Undergoing Mastectomy Phase 4